Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Warfarin dose estimation using clinical and pharmacogenetic data in Chinese patients
ChiCTR-ONC-11001532Phase 4Completed
- Sponsor
- Pharmacogenetics Research Institute, Xiangya Hospital, Central South University
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of warfarin in Atrial fibrillation (AFib), deep vein thrombosis (DVT), pulmonary embolism (PE) and 2 more, sponsored by Pharmacogenetics Research Institute, Xiangya Hospital, Central South University. Primary endpoint: Stable warfarin dosage. Started Mar 2011; status: completed.
02
Drugs
warfarin
03
Conditions
Atrial fibrillation (AFib)deep vein thrombosis (DVT)pulmonary embolism (PE)strokeheart valve prosthesis
Beyond the preview
Go deeper on ChiCTR-ONC-11001532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-11001532.